212 filings
Page 4 of 11
8-K
zgk7l3jfsm17
10 Nov 21
Seres Therapeutics Reports Third Quarter 2021 Financial Results and Provides
7:07am
8-K
9fw1k k191ckt9nsoy
3 Aug 21
Seres Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates
7:14am
8-K
qcbcigm
22 Jul 21
Seres Therapeutics Announces Topline Results for SER-287 Phase 2b Study in Mild-to-Moderate Ulcerative Colitis
7:06am
8-K
p5f2pn
1 Jul 21
Entry into a Material Definitive Agreement
7:29am
8-K
agdumomdl tt
21 Jun 21
Submission of Matters to a Vote of Security Holders
4:06pm
8-K
9rod29 g0na3j3bf1g
21 May 21
Entry into a Material Definitive Agreement
4:42pm
424B5
hke74e25 i8bmped
21 May 21
Prospectus supplement for primary offering
4:38pm
8-K
1r0k 4svu
20 May 21
Seres Therapeutics Announces David Arkowitz to Join as Executive Vice President, Chief Financial Officer and Head of Business Development
8:30am
8-K
5crxqnw9m23
4 May 21
Seres Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Updates
7:47am
DEFA14A
59iwlzkuo5p1gdb
30 Apr 21
Additional proxy soliciting materials
4:08pm
S-8 POS
qvbpkqe4r
3 Mar 21
Registration of securities for employees (post-effective amendment)
12:00am
S-8
qc99bawe83
2 Mar 21
Registration of securities for employees
10:22am
8-K
xfcw6k
2 Mar 21
Seres Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Updates
7:00am
8-K
lc7pe0
1 Feb 21
Departure of Directors or Certain Officers
7:00am
8-K
n7uvro9nt 3adfb1bpav
11 Jan 21
Regulation FD Disclosure
7:00am
8-K
6dfvz3nu
7 Dec 20
Termination of a Material Definitive Agreement
7:03am